Medical Management of Gastroesophageal Reflux Disease

被引:23
作者
Wang, Changcheng [1 ]
Hunt, Richard H. [1 ]
机构
[1] McMaster Univ, Hlth Sci Ctr, Dept Med, Div Gastroenterol, Hamilton, ON L8N 3Z5, Canada
关键词
Gastroesophageal reflux disease (GERD); Proton pump inhibitors (PPIs); Antisecretory therapy; Antireflux surgery;
D O I
10.1016/j.gtc.2008.09.001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Antisecretory therapies that raise intragastric pH provide the best healing of the esophageal mucosal damage that occurs in gastroesophageal reflux disease. Continuous maintenance therapy is also effective to reduce the likelihood of recurrence of esophagitis and control symptoms in the long term. Proton pump inhibitor (PPI) therapy is an effective approach for healing esophagitis and controlling symptoms. Endoscopic and surgical treatments may provide an option for patients who are refractory to PPIs in whom reflux has been clearly demonstrated. Long-term antireflux medication is often needed after surgical treatment because of persisting or recurrent pathologic reflux and symptoms. An alternative approach to controlling transient lower esophageal sphincter relaxations, such as the GABA-B agonists, deserves further study.
引用
收藏
页码:879 / +
页数:22
相关论文
共 130 条
[1]  
Anvari M, 2003, J AM COLL SURGEONS, V196, P58, DOI [10.1016/S1072-7515(02)01604-6, DOI 10.1016/S1072-7515(02)01604-6]
[2]   The pathogenesis of heartburn in nonerosive reflux disease: A unifying hypothesis [J].
Barlow, WJ ;
Orlando, RC .
GASTROENTEROLOGY, 2005, 128 (03) :771-778
[3]  
BEHAR J, 1978, GASTROENTEROLOGY, V74, P441
[4]   APPROPRIATE ACID SUPPRESSION FOR THE MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
BELL, NJV ;
BURGET, D ;
HOWDEN, CW ;
WILKINSON, J ;
HUNT, RH .
DIGESTION, 1992, 51 :59-67
[5]   Use of acid suppressive medications after laparoscopic antireflux surgery: Prevalence and clinical indications [J].
Bonatti, Hugo ;
Bammer, Tanja ;
Achem, Sami R. ;
Lukens, Frank ;
DeVault, Kenneth R. ;
Klaus, Alexander ;
Hinder, Ronald A. .
DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (01) :267-272
[6]   Gastroesophageal reflux disease in primary care - Prevalence, epidemiology and Quality of Life of patients [J].
Bruley Des Varannes, Stanislas ;
Marek, Lizzie ;
Humeau, Benoist ;
Lecasble, Morc ;
Colin, Raymond .
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2006, 30 (03) :364-370
[7]   Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment [J].
Calabrese, C ;
Bortolotti, M ;
Fabbri, A ;
Areni, A ;
Cenacchi, G ;
Scialpi, C ;
Miglioli, M ;
Di Febo, G .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (03) :537-542
[8]   The pattern of esophageal acid exposure in gastroesophageal reflux disease influences the severity of the disease [J].
Campos, GMR ;
Peters, JH ;
DeMeester, TR ;
Öberg, S ;
Crookes, PF ;
Mason, RJ .
ARCHIVES OF SURGERY, 1999, 134 (08) :882-887
[9]   Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease [J].
Castell, D ;
Bagin, R ;
Goldlust, B ;
Major, J ;
Hepburn, B .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (12) :1467-1474
[10]  
CASTELL DO, 2007, GASTROENTEROLOGY S2, V132, pA486